

Pharsight Publications/Abstracts in Pediatric Research

1. **Marier JF, Mouksassi MS**, Pan CC, Breitmeyer JB, and Royal MA. IV Acetaminophen Pharmacokinetics in Children and Adolescents is Comparable to Adults. *Clinical Pharmacology & Therapeutics*, 2010 **87**: P11-72.
2. Pan CC, **Marier JF, Mouksassi MS**, Breitmeyer JB, and Royal MA. Population Pharmacokinetics of Intravenous Acetaminophen in Neonates, Infants, Children, and Adolescents. *Clinical Pharmacology & Therapeutics*, 2010 **87**: O1-A-1.
3. **Mouksassi MS, Marier JF**, Cyran J, and Vinks AA. Clinical Trial Simulations in Pediatric Patients Using Realistic Covariates: Applications to Teduglutide, a Glucagon-Like Peptide 2 Analogue in Neonates and Infants Patients with Short-Bowel Syndrome. *Clin Pharmacol Ther*. 2009;**86**(6):667-71.
4. Pettersen G, **Mouksassi MS**, Théorêt Y, Labbé L, Faure, C, Nguyen B and Litalien C. Population Pharmacokinetics of Intravenous Pantoprazole in Pediatric Intensive Care Patients. *Br J Clin Pharmacol*. 2009 Feb;**67**(2):216-27
5. **Marier JF**, Dubuc MC, Drouin E, Alvarez F, Ducharme MP, and Brazier JL. Pharmacokinetics of Omeprazole in Healthy Adults and in Children with Gastroesophageal Reflux Disease. *Ther Drug Monit*. 2004 Feb;**26**(1):3-8.
6. Zuppa AF, Hammer G, Malviya S, **Mouksassi MS**, Barrett JS, Kenney B, and Royal MA. Pharmacokinetics of IV Acetaminophen in Pediatric Populations. American society of Clinical Pharmacology & Therapeutics (ASCPT). *Annual Meeting; March 18-21, 2009; National Harbor, Maryland*.
7. Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, **Kassir N**, Champagne MA, Doyle J. IV Busulfan Dose Individualization in Children Undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. *Biology of Blood and Marrow Transplantation*. 2008 May;**14**(5):576-82.
8. **Kassir N**, Théorêt Y, Champagne MA, Duval M, Larocque D, and Labbé L. Population pharmacokinetic of intravenous busulfan in children. P11-98. *Clinical Pharmacology & Therapeutics*, 2007, **81**(1): P81.
9. Delaloye J-R, **Kassir N**, Litalien C, Théorêt Y, Alvarez F, Martin S, and Lapeyraque A-L. Limited Sampling Strategies for Tacrolimus Monitoring in Pediatric Liver Transplant Recipients. 2009, 5th *Congress of the International Pediatric Transplant Association, Istanbul, Turkey*.
10. **Kassir N**, Théorêt Y, Litalien C, Tapiero B, Duval M, Labbé L and Ovetchkine P. Population Pharmacokinetics of Intravenous and Oral Voriconazole in Children. 2009, *49th Annual ICAAC Meeting, San Francisco*.
11. **Mouksassi MS** and **Marier JF**. Modeling and Simulation for Optimal Drug Development in Pediatric Populations. *Presented at: 2nd World Conference on Magic Bullets (Ehrlich II); October 3-5, 2008; Nürnberg, Germany*.
12. **Kassir N**, Théorêt Y, Champagne MA, Duval M, Larocque D, and Labbé L. Population Pharmacokinetic of Intravenous Busulfan in Children before Hematopoietic Stem Cell Transplantation. 2007, *AFPC Annual Meeting*.
13. **Mouksassi MS**, Pettersen G, Theoret Y, Labbé L, Faure, C, Nguyen B and Litalien C. Population Pharmacokinetics of Intravenous Pantoprazole in Pediatric Intensive Care Patients. [Poster Presentation]. *AFPC Annual Meeting; May 19-23 2007*.
14. Pettersen G, Faure, C, Litalien C, Théorêt Y, **Mouksassi MS**, Labbé L, and Nguyen B. Pharmacokinetics of intravenous pantoprazole in critically ill children: impact of systemic inflammatory response syndrome. 231-t. *Critical Care Medicine. Society of Critical Care Medicine 35th Critical Care Congress January, 7-11, 2006,33*(12).

Pharsight Publications/Abstracts in Pediatric Research (continued)

15. Pettersen G, Faure, C, Litalien C, Théorêt Y, **Mouksassi MS**, Nguyen B, Labbé L, and Proietti A. Therapeutic Failure of a Single Intravenous Dose of Pantoprazole in Young Intensive Care Children. 232-t. Critical Care Medicine. *Society of Critical Care Medicine 35th Critical Care Congress, January 7-11, 2006*,33(12).
16. **Jayaraman B** and Barrett JS. A SAS-based Query and Exploitation Interface to Hospital Drug Utilization Data – *ACCP Annual Meeting, 2008*.
17. Barrett JS, Norris R, Vijayakumar S, Mondick J, Vijayakumar K, **Jayaraman B**, Cummins E, Narayan M, Zuppa A, and Skolnik, JM. Enhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records. *Oral abstracts PAGE 2008 meeting, Marseille, France*.
18. Menon D, Mondick JT, **Jayaraman B**, Cheung AT and Barrett JS. Pharmacokinetics and Pharmacodynamics of Intravenous Nicardipine in Anesthetized Cardiac Surgical Patients. *J Clin Pharmacol 47(9): 1205, (Abstr 99), 2007*.
19. **Jayaraman B**, Skolnik JM, Patel D and Barrett JS. SAS-based Discrete Event Simulation (DES) to Evaluate Pediatric Oncology Phase I Trial Designs. *J Clin Pharmacol 47(9): 1203, (Abstr 87), 2007*.
20. Barrett JS, Skolnik J, **Jayaraman B**, Patel D, and Adamson P. Improving Study Design and Conduct Efficiency of Event-Driven Clinical Trials via Discrete Event Simulation: Application to Pediatric Oncology. *AGE 16 (2007) Abstr 1075 [www.page-meeting.org/?abstract=1075]*.
21. Menon D, Mondick JT, **Jayaraman B**, Cheung AT, and Barrett JS. Pharmacokinetics/Pharmacodynamics of Intravenous Bolus Nicardipine in Adults Undergoing Cardiovascular Surgery. *PAGE 16 (2007) Abstr 1186 [www.page-meeting.org/?abstract=1186]*.
22. **Jayaraman B**, Gupta M, and Barrett JS: A SAS Based Solution to the Rapid Assembly, Execution and Processing of NONMEM Jobs for Population Based Analyses. *ACCP 2006*.
23. Zuppa AF, **Jayaraman B**, Blumer J, Reed M, and Barrett JS: Cross-institutional Drug Utilization in Pediatric Intensive Care Units. *ACCP 2006*.
24. Gupta M, Wade KC, **Jayaraman B**, Mondick J, and Barrett JS: Optimizing Fluconazole Dosing in Preterm Neonates Based on Simulations from Posterior Parameter (Uncertainty) Distributions (*PAGE 15 (2006) Abstr 1021 [www.page-meeting.org/?abstract=1021]*).
25. Barrett JS, Vijayakumar K, Krishnaswami S, Gupta M, Mondick J, **Jayaraman B**, Muralidharan A, Santhanam S, and Vijayakumar S: iClinical NONMEM Workbench (*PAGE 15 (2006) Abstr 1016 [www.page-meeting.org/?abstract=1016]*).
26. Wade KC, Gupta M, **Jayaraman B**, Wu D, Adamson P, and Barrett JS: Consideration for Optimizing Fluconazole Dosing in Preterm Neonates Based on Modeling and Simulation Approaches. *Pediatric Academic Societies' Annual Meeting, 2006*.
27. Narayan M, Barrett JS, **Jayaraman B**, Gupta M, Mondick J, and Patel D: Creation of the collaborative scientific workbench (CSW) for Multidisciplinary Research. *J Clin Pharmacol 45 (2005), P96, p. 1090*.
28. Zuppa A, Vijayakumar S, **Jayaraman B**, Patel D, Narayan M, Vijayakumar K, Mondick JT, and Barrett JS. An informatics approach to assess pediatric pharmacotherapy design and implementation of a hospital drug utilization system. *J Clin Pharmacol. 2007 Sep;47(9):1172-80*.
29. Barrett JS, Skolnik J, **Jayaraman B**, Patel D, and Adamson P. Discrete Even simulation applied to pediatric phase I oncology designs. *Clin Pharmacol Ther. 2008 Dec;84(6):729-33*.
30. Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, Ramey N, **Jayaraman B**, Hoppu K, Adamson PC, Gastonguay MR, and Barrett JS; National Institute of Child Health and Development Pediatric Pharmacology Research Unit Network. Population pharmacokinetics of fluconazole in young infants. *Antimicrob Agents Chemother. 2008 Nov;52(11):4043-9*.

Pharsight Publications/Abstracts in Pediatric Research (continued)

31. Menon-Andersen D, Mondick JT, **Jayaraman B**, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, and Barrett JS. Population pharmacokinetics of Imatinib mesylate and its metabolite in children and young adults. *Cancer Chemother Pharmacol*. 2009 Jan;63(2):229-38.
32. Barrett JS, **Jayaraman B**, Patel D, and Skolnik JM. A SAS based solution to evaluate design efficiency of phase I pediatric oncology trials via discrete event simulation. *Comput Methods Programs Biomed*. 2008 Jun 90(3):240-50.
33. Skolnik JM, Barrett JS, **Jayaraman B**, Patel D, and Adamson PC Shortening the timeline of pediatric phase I trials, the rolling six design. *J Clin Oncol*. 2008 Jan 10; 26(2):190-5.
34. Barrett JS, Patel D, **Jayaraman B**, Narayan M, and Zuppa A Key performance indicators for the assessment of pediatric pharmacotherapeutic guidance. *J Pediatric Pharmacology and Therapeutics* Vol 13(3).
35. **Kassir N**, Litalien C, Théorêt Y, Labbé L. Population pharmacokinetic for oral tacrolimus in pediatric liver transplant recipients. *Manuscript submitted to JCP*.
36. Launay E, **Kassir N**, Théorêt Y, Litalien C, Duval M, Alvarez F, Lapeyraque A-L, Larocque D, Lamarre V, and Ovetchkine P. Pharmacokinetic Profile of Valganciclovir in Pediatric Transplant Recipients. *Manuscript submitted to JCP*.
37. **Kassir N**, Théorêt Y, Champagne MA, Duval M, **Mouksassi MS**, Larocque D, and Labbé L. Population pharmacokinetic of intravenous busulfan in children before hematopoietic stem cell transplantation. *Manuscript submitted to JCP*.
38. Lichter-Konecki U, Diaz GA, Merritt L, Feigenbaum A, **Jomphe C**, **Marier JF**, **Beliveau M**, Mauney J, Dickinson K, Martinez A, Mokhtarani M, Scharschmidt B, and Rhead W. Ammonia (NH₃) Control in Children with Urea Cycle Disorders (UCDs): Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. *Abstract submitted to the American Society of Human Genetics (ASHG)*.
39. **NH Gosselin**, **MS Mouksassi**, **JF Marier**, JB Breitmeyer, MA Royal. IV Acetaminophen Overdose Simulations: Guidance for Making Decisions on Early Treatment of IV Overdoses. Submitted to American Society for Clinical Pharmacology and Therapeutics.
40. **JF Marier PhD, FCP, MS Mouksassi, PharmD, N Gosselin**, M. A. Royal, L. Fong, C. Pan, R. Ang, JB Breitmeyer. Population Pharmacokinetics of Intravenous Acetaminophen in Neonates, Infants, Children and Adolescents. Manuscript in Preparation.
41. **NH Gosselin, MS Mouksassi, JF Marier**, JB Breitmeyer, MA Royal. Trial Simulations of IV Acetaminophen Dosing Simulations in Neonates and Infants to Support Optimal Dosing Regimen in Neonates and Infants. Submitted to American Society for Clinical Pharmacology and Therapeutics.
42. Uta Lichter-Konecki, GA Diaz, JL Merritt II, A Feigenbaum, **C Jomphe, JF Marier, M Beliveau, J Mauney, K Dickinson, A Martinez, M Mokhtarani, B Scharschmidt, W Rhead**. Ammonia Control in Children with Urea Cycle Disorders (UCDs); Phase 2 Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate.
43. **Marchand M**, Fuseau E, Critchley DJ. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. *J Pharmacokinetic Pharmacodyn*. 2010 Feb;37(1):99-118.
44. Harnisch L, **Chanu P**, Dykstra K, **Claret L, Bruno R**, Gao X. Hemodynamics as a Substitute for Exercise Capacity Endpoints in Patients with Pulmonary Arterial Hypertension: A Model Based Assessment for Sildenafil. Presented at European Respiratory Society, September 19, 2010.
45. Dombrowsky E, **Jayaraman B**, Narayan M, Barrett JS Evaluation performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer (The Drug Monit 2011 Feb; 33(1): 99-107.